Sign up
Pharma Capital

Resapp Health embarking on new study to evaluate efficacy

Study represents another step towards the commercialisation of ResAppDx in the US.
Picture of a doctor with a child
The trial data is expected to be more representative of ResAppDx’s performance

Resapp Health Ltd (ASX:RAP), a developer of smartphone applications for the diagnosis and management of respiratory disease, has enrolled the first patient in its SMARTCOUGH-C-2 study in the United States.

The study is a prospective double blind study to evaluate the efficacy of the ResAppDx smartphone application in diagnosing childhood respiratory diseases from cough sounds.

The SMARTCOUGH-C-2 study plans to enrol up to 1,667 patients aged 29 days to 12 years of age who have signs or symptoms of respiratory disease.

Clinical diagnosis made by independent committee

The study covers conditions such as pneumonia, lower respiratory tract disease, viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease and croup.

The clinical diagnosis will be made by an independent, centralised clinical adjudication committee using all available clinical data, including radiology and microbiology.

This represents another step towards the commercialisation of ResAppDx in the United States.

The refined study includes major improvements over previous studies in the United States, which should deliver results that are more representative of ResAppDx’s performance. 

Register here to be notified of future RAP Company articles
View full RAP profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.